SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Novartis seen facing hit as cholesterol trial fails late-stage endpoint

J.P. Morgan analysts said late-stage results for a cholesterol drug candidate failed to reduce severe cardiovascular events such as heart attacks and strokes, putting pressure on Novartis shares.

NOT

Novartis shares are likely to take a hit after a cholesterol drug candidate failed to reduce the risk of severe cardiovascular events such as heart attacks and strokes in a late-stage trial, J.P. Morgan analysts said in a research note. Consensus estimates for Novartis included $1 billion in 2…

Related stories